کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5815992 | 1556654 | 2011 | 11 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Evaluation of the D3 dopamine receptor selective agonist/partial agonist PG01042 on l-dopa dependent animal involuntary movements in rats
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
6-OHDATMSD3 dopamine receptorss.c.MFBPG01037GIRKMPTPi.p.6-HydroxydopaminePLDAMGLIDPFC1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine - 1-methyl-4-phenyl-1،2،3،6-tetrahydropyridineDMSO - DMSOl-DOPA - L-DOPAAmygdala - آمیگدال، بادامهmedial forebrain bundle - بسته نرم افزاری پروبیالParkinson’s disease - بیماری پارکینسونsubstantia nigra - توده سیاهabnormal involuntary movement - حرکت غیرمعمول غیر طبیعیintraperitoneal - داخل صفاقیdyskinesia - دیسکینزیL-DOPA-induced dyskinesia - دیسکینزی ناشی از L-DOPADimethylsulfoxide - دیمتیل سولفواکسیدsubcutaneous - زیر جلدیPhospholipase D - فسفولیپاز Dprefrontal cortex - قشر prefrontalAIM - هدفGlobus pallidus - گوی رنگ پریده، گلوبوس پالیدوسDopamine receptors - گیرنده های دوپامین
موضوعات مرتبط
علوم زیستی و بیوفناوری
علم عصب شناسی
علوم اعصاب رفتاری
پیش نمایش صفحه اول مقاله

چکیده انگلیسی
The substituted 4-phenylpiperazine D3 dopamine receptor selective antagonist PG01037 ((E)-N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)but-2-enyl)-4-(pyridin-2-yl)benzamide) was reported to attenuate l-dopa-associated abnormal involuntary movements (AIMs) in unilaterally lesioned rats, a model of l-dopa-dependent dyskinesia in patients with Parkinson's Disease (Kumar et al., 2009a). We now report that PG01042 (N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-3-yl)benzamide), which is a D3 dopamine receptor selective agonist for adenylyl cyclase inhibition and a partial agonist for mitogenesis, is also capable of attenuating AIMs scores. The intrinsic activity of PG01037 and PG01042 were determined using a) a forskolin-dependent adenylyl cyclase inhibition assay and b) an assay for agonist-associated mitogenesis. It was observed that the in vivo efficacy of PG01042 increased when administered by intraperitoneal (i.p.) injection simultaneously with l-dopa/benserazide (8 mg/kg each), as compared to a 60 min or 30 min pretreatment. PG01042 was found to attenuate AIM scores in these animals in a dose dependent manner. While PG01042 did not effectively inhibit SKF 81297-dependent AIMs, it inhibited apomorphine-dependent AIM scores. Rotarod studies indicate that PG01042 at a dose of 10 mg/kg did not adversely affect motor coordination of the unilaterally lesioned rats. Evaluation of lesioned rats using a cylinder test behavioral paradigm indicated that PG01042 did not dramatically attenuate the beneficial effects of l-dopa. These studies and previously published studies suggest that both D3 dopamine receptor selective antagonists, partial agonists and agonists, as defined by an adenylyl cyclase inhibition assay and a mitogenic assay, are pharmacotherapeutic candidates for the treatment of l-dopa-associated dyskinesia in patients with Parkinson's Disease.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Neuropharmacology - Volume 60, Issues 2â3, FebruaryâMarch 2011, Pages 284-294
Journal: Neuropharmacology - Volume 60, Issues 2â3, FebruaryâMarch 2011, Pages 284-294
نویسندگان
Lindsay R. Riddle, Rakesh Kumar, Suzy A. Griffin, Peter Grundt, Amy Hauck Newman, Robert R. Luedtke,